NASDAQ:IMUX

Immunic Competitors

$12.92
-0.52 (-3.87 %)
(As of 04/20/2021 11:51 AM ET)
Add
Compare
Today's Range
$12.60
Now: $12.92
$13.37
50-Day Range
$14.21
MA: $15.34
$16.85
52-Week Range
$7.50
Now: $12.92
$28.21
Volume3,088 shs
Average Volume226,671 shs
Market Capitalization$273.49 million
P/E RatioN/A
Dividend YieldN/A
Beta2.21

Competitors

Immunic (NASDAQ:IMUX) Vs. PHAT, KRON, OMER, STOK, YMAB, and MRSN

Should you be buying IMUX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Immunic, including Phathom Pharmaceuticals (PHAT), Kronos Bio (KRON), Omeros (OMER), Stoke Therapeutics (STOK), Y-mAbs Therapeutics (YMAB), and Mersana Therapeutics (MRSN).

Immunic (NASDAQ:IMUX) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, dividends, risk, profitability and institutional ownership.

Profitability

This table compares Immunic and Phathom Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunicN/A-46.33%-42.50%
Phathom PharmaceuticalsN/A-88.73%-69.04%

Valuation & Earnings

This table compares Immunic and Phathom Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunicN/AN/A$-34,930,000.00($4.52)-2.87
Phathom PharmaceuticalsN/AN/A$-255,130,000.00($13.98)-2.49

Immunic is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Immunic has a beta of 2.21, suggesting that its share price is 121% more volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Immunic and Phathom Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immunic001003.00
Phathom Pharmaceuticals10402.60

Immunic presently has a consensus target price of $59.5556, indicating a potential upside of 354.62%. Phathom Pharmaceuticals has a consensus target price of $53.00, indicating a potential upside of 48.83%. Given Immunic's stronger consensus rating and higher possible upside, research analysts clearly believe Immunic is more favorable than Phathom Pharmaceuticals.

Institutional and Insider Ownership

41.3% of Immunic shares are owned by institutional investors. Comparatively, 73.8% of Phathom Pharmaceuticals shares are owned by institutional investors. 12.1% of Immunic shares are owned by company insiders. Comparatively, 39.8% of Phathom Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Immunic beats Phathom Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

Immunic (NASDAQ:IMUX) and Kronos Bio (NASDAQ:KRON) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Immunic and Kronos Bio, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immunic001003.00
Kronos Bio00403.00

Immunic currently has a consensus price target of $59.5556, indicating a potential upside of 354.62%. Kronos Bio has a consensus price target of $43.6667, indicating a potential upside of 117.14%. Given Immunic's higher probable upside, research analysts clearly believe Immunic is more favorable than Kronos Bio.

Profitability

This table compares Immunic and Kronos Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunicN/A-46.33%-42.50%
Kronos BioN/AN/AN/A

Earnings & Valuation

This table compares Immunic and Kronos Bio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunicN/AN/A$-34,930,000.00($4.52)-2.87
Kronos BioN/AN/AN/AN/AN/A

Institutional & Insider Ownership

41.3% of Immunic shares are held by institutional investors. 12.1% of Immunic shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Immunic beats Kronos Bio on 4 of the 6 factors compared between the two stocks.

Omeros (NASDAQ:OMER) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Institutional and Insider Ownership

56.6% of Omeros shares are held by institutional investors. Comparatively, 41.3% of Immunic shares are held by institutional investors. 11.3% of Omeros shares are held by insiders. Comparatively, 12.1% of Immunic shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Omeros and Immunic's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Omeros$111.81 million10.23$-84,490,000.00($0.96)-19.24
ImmunicN/AN/A$-34,930,000.00($4.52)-2.87

Immunic has lower revenue, but higher earnings than Omeros. Omeros is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Omeros and Immunic, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Omeros02402.67
Immunic001003.00

Omeros presently has a consensus price target of $23.40, indicating a potential upside of 27.45%. Immunic has a consensus price target of $59.5556, indicating a potential upside of 354.62%. Given Immunic's stronger consensus rating and higher probable upside, analysts plainly believe Immunic is more favorable than Omeros.

Profitability

This table compares Omeros and Immunic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Omeros-134.59%N/A-59.49%
ImmunicN/A-46.33%-42.50%

Risk & Volatility

Omeros has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, Immunic has a beta of 2.21, meaning that its share price is 121% more volatile than the S&P 500.

Summary

Immunic beats Omeros on 9 of the 13 factors compared between the two stocks.

Immunic (NASDAQ:IMUX) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Profitability

This table compares Immunic and Stoke Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunicN/A-46.33%-42.50%
Stoke TherapeuticsN/A-22.93%-22.26%

Analyst Ratings

This is a summary of current recommendations for Immunic and Stoke Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immunic001003.00
Stoke Therapeutics02602.75

Immunic currently has a consensus target price of $59.5556, indicating a potential upside of 354.62%. Stoke Therapeutics has a consensus target price of $64.3333, indicating a potential upside of 110.65%. Given Immunic's stronger consensus rating and higher possible upside, equities analysts clearly believe Immunic is more favorable than Stoke Therapeutics.

Insider and Institutional Ownership

41.3% of Immunic shares are owned by institutional investors. 12.1% of Immunic shares are owned by company insiders. Comparatively, 54.6% of Stoke Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Immunic has a beta of 2.21, indicating that its stock price is 121% more volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500.

Earnings and Valuation

This table compares Immunic and Stoke Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunicN/AN/A$-34,930,000.00($4.52)-2.87
Stoke TherapeuticsN/AN/A$-32,330,000.00($1.80)-16.51

Stoke Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Summary

Immunic beats Stoke Therapeutics on 6 of the 11 factors compared between the two stocks.

Y-mAbs Therapeutics (NASDAQ:YMAB) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, profitability and institutional ownership.

Profitability

This table compares Y-mAbs Therapeutics and Immunic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Y-mAbs TherapeuticsN/A-74.98%-66.70%
ImmunicN/A-46.33%-42.50%

Analyst Recommendations

This is a breakdown of recent ratings for Y-mAbs Therapeutics and Immunic, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Y-mAbs Therapeutics02602.75
Immunic001003.00

Y-mAbs Therapeutics currently has a consensus price target of $58.1429, indicating a potential upside of 124.84%. Immunic has a consensus price target of $59.5556, indicating a potential upside of 354.62%. Given Immunic's stronger consensus rating and higher possible upside, analysts clearly believe Immunic is more favorable than Y-mAbs Therapeutics.

Insider and Institutional Ownership

53.2% of Y-mAbs Therapeutics shares are owned by institutional investors. Comparatively, 41.3% of Immunic shares are owned by institutional investors. 38.4% of Y-mAbs Therapeutics shares are owned by insiders. Comparatively, 12.1% of Immunic shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Y-mAbs Therapeutics has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500. Comparatively, Immunic has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500.

Earnings & Valuation

This table compares Y-mAbs Therapeutics and Immunic's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Y-mAbs TherapeuticsN/AN/A$-81,030,000.00($2.30)-11.33
ImmunicN/AN/A$-34,930,000.00($4.52)-2.87

Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Summary

Immunic beats Y-mAbs Therapeutics on 8 of the 11 factors compared between the two stocks.

Mersana Therapeutics (NASDAQ:MRSN) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, profitability and institutional ownership.

Profitability

This table compares Mersana Therapeutics and Immunic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mersana Therapeutics-8,772.91%-45.16%-37.53%
ImmunicN/A-46.33%-42.50%

Analyst Recommendations

This is a breakdown of recent ratings for Mersana Therapeutics and Immunic, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mersana Therapeutics02502.71
Immunic001003.00

Mersana Therapeutics currently has a consensus price target of $26.1667, indicating a potential upside of 65.30%. Immunic has a consensus price target of $59.5556, indicating a potential upside of 354.62%. Given Immunic's stronger consensus rating and higher possible upside, analysts clearly believe Immunic is more favorable than Mersana Therapeutics.

Insider and Institutional Ownership

41.3% of Immunic shares are owned by institutional investors. 5.3% of Mersana Therapeutics shares are owned by insiders. Comparatively, 12.1% of Immunic shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Mersana Therapeutics has a beta of 2.54, suggesting that its stock price is 154% more volatile than the S&P 500. Comparatively, Immunic has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500.

Earnings & Valuation

This table compares Mersana Therapeutics and Immunic's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mersana Therapeutics$42.12 million25.93$-28,210,000.00($0.65)-24.34
ImmunicN/AN/A$-34,930,000.00($4.52)-2.87

Mersana Therapeutics has higher revenue and earnings than Immunic. Mersana Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Summary

Immunic beats Mersana Therapeutics on 7 of the 13 factors compared between the two stocks.

Ad PulseStocks
Rare EV Stock Alert
The world is moving towards EV and this stock is seeing the upwards trend.

Immunic Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$34.76-4.2%$1.13 billionN/A-2.49
Kronos Bio logo
KRON
Kronos Bio
1.7$19.65-2.3%$1.13 billionN/A0.00
Omeros logo
OMER
Omeros
1.4$18.47-2.1%$1.12 billion$111.81 million-7.76News Coverage
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$29.72-2.8%$1.12 billionN/A-16.51
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.07-2.4%$1.11 billionN/A-8.78Increase in Short Interest
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$15.82-0.9%$1.10 billion$42.12 million-11.72
NKTX
Nkarta
1.8$32.16-1.1%$1.07 billionN/A0.00
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$15.61-0.9%$1.06 billionN/A-6.59Upcoming Earnings
Zogenix logo
ZGNX
Zogenix
1.7$18.60-1.7%$1.05 billion$3.65 million-1.96
MannKind logo
MNKD
MannKind
1.4$4.20-1.0%$1.04 billion$63.04 million-20.00Increase in Short Interest
News Coverage
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$21.92-1.7%$1.03 billionN/A-8.09
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$26.21-1.4%$1.03 billionN/A0.00News Coverage
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$19.84-2.1%$1.02 billionN/A-6.53Increase in Short Interest
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
2.0$29.05-2.2%$1.02 billion$57.05 million0.00Analyst Report
Gap Down
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.90-0.5%$1.01 billion$800.40 million23.49
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$50.14-0.5%$1.01 billion$122.47 million-27.55
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$9.30-3.5%$992.09 million$120,000.00-3.44Analyst Report
News Coverage
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$36.53-1.0%$970.00 million$20.79 million-12.60
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$22.40-1.6%$954.57 millionN/A-7.72
Prothena logo
PRTA
Prothena
2.1$22.65-4.9%$950.54 million$810,000.00-8.85
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$26.80-1.0%$941.57 millionN/A-12.35
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$14.21-36.4%$934.81 million$1.52 million-7.56Increase in Short Interest
News Coverage
Gap Down
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$17.92-0.2%$920.14 millionN/A0.00
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.39-0.3%$902.28 million$227.19 million45.53Analyst Downgrade
Radius Health logo
RDUS
Radius Health
1.3$18.86-0.2%$886.30 million$173.32 million-7.73
Ardelyx logo
ARDX
Ardelyx
1.6$8.50-3.6%$868.88 million$5.28 million-8.42Increase in Short Interest
Affimed logo
AFMD
Affimed
1.6$9.37-2.7%$849.70 million$23.96 million-15.88Earnings Announcement
Analyst Report
Analyst Revision
Merus logo
MRUS
Merus
1.8$22.35-1.1%$842.61 million$31.13 million-7.28
ESSA Pharma logo
EPIX
ESSA Pharma
1.6$24.90-0.1%$840.11 millionN/A-23.06
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.7$17.24-0.3%$825.04 million$322.36 million123.14
Annexon logo
ANNX
Annexon
1.9$21.72-0.9%$821.16 millionN/A0.00
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$23.03-1.0%$818.85 million$296.70 million47.00Analyst Revision
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.6$32.69-1.4%$814.84 millionN/A-9.70News Coverage
Epizyme logo
EPZM
Epizyme
1.8$7.80-0.9%$786.80 million$23.80 million-3.50Analyst Report
News Coverage
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$21.26-1.0%$772.43 millionN/A0.00Increase in Short Interest
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.2$27.04-0.6%$751.39 million$148.36 million-7.02
Humanigen logo
HGEN
Humanigen
1.7$13.72-1.2%$742.87 millionN/A0.00Analyst Report
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$19.17-3.4%$709.73 million$6.83 million-19.76
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$4.84-0.0%$698.67 million$322.07 million-4.61Upcoming Earnings
Decrease in Short Interest
News Coverage
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$9.20-0.3%$692.81 million$40.89 million-3.17News Coverage
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.14-0.0%$675.74 million$150,000.00-4.49News Coverage
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$26.60-1.2%$671.97 million$19.56 million-19.14
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$2.61-1.1%$670.57 million$2.22 million-15.35News Coverage
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$20.21-0.1%$666.59 million$252 million-2.07
Chimerix logo
CMRX
Chimerix
1.3$7.73-0.5%$665.73 million$12.52 million-13.56
Veru logo
VERU
Veru
1.4$8.90-2.1%$653.68 million$42.59 million-31.78Analyst Report
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.4$14.79-3.7%$650.06 million$17.26 million-4.11
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$28.25-0.5%$648.83 million$13.80 million-13.65Analyst Report
News Coverage
Kadmon logo
KDMN
Kadmon
1.8$3.71-0.0%$637.44 million$5.09 million-6.18
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$8.17-2.4%$632.17 millionN/A-2.29Increase in Short Interest
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.